Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Today Portal Instruments announced a joint publication with Regeneron on the PRIME needle-free injection platform. The findings provided crucial data on Portal's platform, demonstrating the ability to deliver high-viscosity biologics with volume flexibility and tailored injection depths.
● Portal Instruments and Regeneron publish new data demonstrating Portal’s PRIME® needle-free injection technology for large volume injections — engineering insights that directly informed the design of the latest PRIME NEXUS™ needle-assisted platform.
● PRIME NEXUS™ leverages Portal’s decade-long experience of reusable needle-free expertise to deliver high-viscosity biologics with tailored injection depth, volume flexibility, and reduced development risk.
Portal Instruments, a leader in advanced drug delivery technology, today announced the publication of a collaborative study with Regeneron Pharmaceuticals in Bioengineering & Translational Medicine. The study highlights the capabilities of Portal’s proprietary needle-free, high-pressure auto injection platform, PRIME®, to deliver challenging biologics with precision, speed, and patient comfort — foundational expertise that has directly informed the company’s newest product, the PRIME NEXUS™ needle-assisted reusable autoinjector platform.
The study demonstrates that Portal’s novel, computer-controlled, needle-free injector can safely and effectively deliver high-viscosity (>50 cP, 2 mL) monoclonal antibody formulations subcutaneously, achieving bioavailability, pharmacokinetics, and product integrity comparable to conventional needle-and-syringe injections. These findings underscore the potential of Portal’s platform technology as a patient-friendly and scalable solution for the delivery of complex biologics.
For over a decade, Portal has been at the forefront of needle-free injection science, developing unparalleled expertise in the physics of drug delivery physics — from fluid dynamics and viscosity management to injection depth control. This know-how is now powering a new generation of drug delivery systems. While PRIME NEXUS™ is a needle-assisted autoinjector, it builds directly on Portal’s deep engineering legacy to optimize performance for high-viscosity biologics, variable fill volumes, and complex injection profiles.
“This work builds on our deep expertise with our proprietary linear actuator platform and directly informs our PRIME NEXUS™ product, as both devices leverage the same core technology,” said Dr. Patrick Anquetil, CEO at Portal Instruments. “This shared engineering foundation enables us to accelerate innovation, reduce development risk, and bring to market a highly differentiated platform for high-viscosity biologics and other challenging therapies.”
“Regeneron’s expertise in developing high-concentration monoclonal antibodies made them the ideal partner to rigorously challenge our needle-free PRIME® platform,” said Marc Pelletier, PhD, Senior Director, System Research & Design at Portal Instruments. “Together, we demonstrated that PRIME® could generate the pressure and control needed to consistently deliver high-viscosity formulations subcutaneously, producing PK profiles comparable to those of needle-and-syringe (N&S). The collaboration also provided critical insights into the dynamics of large-volume, high-viscosity subcutaneous delivery through a N&S system, which we directly applied to advance our PRIME NEXUS™ needle-assisted platform toward a more streamlined, consistent patient experience.”
With PRIME NEXUS™, pharmaceutical partners can expect:
● Tailored performance — precisely optimized for viscosity, injection depth, and volume.
● Streamlined development — reduced technical risk through proven platform continuity.
● Enhanced patient experience — drawing on Portal’s human-factor insights from over a decade of experience in reusable needle-free injection technologies.
The recently published Regeneron study underscores the engineering rigor and cross-platform design strategy behind both PRIME® and PRIME NEXUS™, highlighting Portal’s ability to rapidly advance reusable injection solutions for the next wave of complex biologic therapies.
For more information about PRIME® or PRIME NEXUS™ and Portal’s advanced injection technologies, visit www.portalinstruments.com.
The peer-reviewed publication is available at: https://aiche.onlinelibrary.wiley.com/doi/10.1002/btm2.70063
About Portal InstrumentsPortal Instruments is a privately held medical device company focused on developing and commercializing innovative drug delivery platform technologies that transform the administration of injectable medications. Portal's mission is to improve patient experience, adherence, and outcomes through advanced, user-centric delivery solutions.
Portal Instruments will showcase PRIME NEXUS™ and its expanding delivery solutions at upcoming industry events, including PDA, PODD, CPhI.
Contact us to learn more and schedule a time to connect at these events
Steven Kaufman
Portal Instruments Inc.
617-500-4348
steven.kaufman@portalinstruments.com
July 2021 - Many undergraduate students get the opportunity to complete a summer internship. Some participate in a Co-Op; a 6-month long internship where students are able to fully immerse themselves in a full-time employment position to better understand their place in the workspace.
Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Please fill out the details below and we will get back to you shortly.